



4th April 2024

FOR PUBLIC RELEASE

Rua Bioscience partners with AlphaFarma for supply to Germany

Tairawhiti, New Zealand – New Zealand medicinal cannabis company Rua Bioscience is continuing to grow its presence in Germany and has signed a commercial supply agreement with Malta-based AlphaFarma.

AlphaFarma will supply Rua with dried flower medicinal cannabis products for the German market, expanding the Rua range available through its distribution partner Nimbus Health.

“Germany is one of the largest and most developed medicinal cannabis market in Europe,” said Rua CEO Paul Naske.

“In April 2023 Rua successfully launched our first GMP-quality medicines into this market, marking a critical commercial milestone for the company.

“Our agreement with AlphaFarma will further strengthen our supply lines, as we look to grow our sales presence with an expanded product portfolio and supply channels. We anticipate having these products in the market before the end of the financial year.

“Our longer-term strategy is to supply products produced using our genetics from Ruatorea through this established sales pipeline into the key market of Germany.”

AlphaFarma was initially established as a manufacturer, agent and distributor of medical disposables and medical equipment in Malta and North Africa, and now exports a broad range of products worldwide. Since 2015 it has been owned by a conglomerate of pharmacists, doctors and pharmaceutical managers, combining pharma and medical know-how with commercial expertise.

ENDS

The person who authorised this announcement:

Paul Naske

Chief Executive Officer

paul.naske@ruabio.com

+64 21 445154

For media inquiries, please contact:

Paul Naske - paul.naske@ruabio.com